Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.13)
# 1,530
Out of 4,442 analysts
302
Total ratings
39.4%
Success rate
8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Reiterated: Buy | $8 | $4.08 | +96.08% | 35 | Jun 17, 2026 | |
| PHAT Phathom Pharmaceuticals | Reiterated: Buy | $26 | $10.86 | +139.41% | 20 | Jun 17, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $15.07 | +45.99% | 15 | Jun 8, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $20.21 | +117.77% | 14 | Jun 8, 2026 | |
| UPB Upstream Bio | Initiated Coverage: Buy | $36 | $6.32 | +469.62% | 1 | Jun 3, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $25.61 | +118.66% | 19 | Jun 1, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | $88 | $66.17 | +32.99% | 9 | May 26, 2026 | |
| SRZN Surrozen | Maintained: Buy | $44 | $24.86 | +76.99% | 9 | May 26, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $48 → $38 | $5.75 | +560.87% | 16 | May 12, 2026 | |
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $2.02 | -0.99% | 31 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $37.05 | +56.55% | 15 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $11.60 | +210.34% | 31 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $1.10 | +445.45% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $6.28 | +91.08% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $6.18 | +191.26% | 7 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $8 | $0.7503 | +966.24% | 12 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.02 | - | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.67 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $9.95 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $70.45 | n/a | 5 | Oct 21, 2022 |
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $8
Current: $4.08
Upside: +96.08%
Phathom Pharmaceuticals
Jun 17, 2026
Reiterated: Buy
Price Target: $26
Current: $10.86
Upside: +139.41%
Immunic
Jun 8, 2026
Reiterated: Buy
Price Target: $22
Current: $15.07
Upside: +45.99%
Zenas BioPharma
Jun 8, 2026
Reiterated: Buy
Price Target: $44
Current: $20.21
Upside: +117.77%
Upstream Bio
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $6.32
Upside: +469.62%
Mineralys Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $56
Current: $25.61
Upside: +118.66%
Tarsus Pharmaceuticals
May 26, 2026
Maintained: Buy
Price Target: $88
Current: $66.17
Upside: +32.99%
Surrozen
May 26, 2026
Maintained: Buy
Price Target: $44
Current: $24.86
Upside: +76.99%
LENZ Therapeutics
May 12, 2026
Reiterated: Buy
Price Target: $48 → $38
Current: $5.75
Upside: +560.87%
Aldeyra Therapeutics
May 11, 2026
Reiterated: Hold
Price Target: $2
Current: $2.02
Upside: -0.99%
May 11, 2026
Reiterated: Buy
Price Target: $58
Current: $37.05
Upside: +56.55%
May 11, 2026
Reiterated: Buy
Price Target: $36
Current: $11.60
Upside: +210.34%
May 8, 2026
Reiterated: Buy
Price Target: $6
Current: $1.10
Upside: +445.45%
May 8, 2026
Reiterated: Buy
Price Target: $12
Current: $6.28
Upside: +91.08%
May 1, 2026
Reiterated: Buy
Price Target: $18
Current: $6.18
Upside: +191.26%
Apr 16, 2026
Maintained: Buy
Price Target: $80 → $8
Current: $0.7503
Upside: +966.24%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.02
Upside: -
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $3.67
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Maintained: Buy
Price Target: $39
Current: $9.95
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $70.45
Upside: n/a